The i-micro trial, ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial—study protocol for a randomized controlled trial

HIGHLIGHTS

• who: Matthieu Legrand from the Department of Anaesthesiology, Critical Care Medicine and Burn Unit, and Lariboisière University Hospitals, AParé, Paris, France have published the research work: The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial—study protocol for a randomized controlled trial, in the Journal: (JOURNAL) of 28/Dec/2018
• what: The trial aims to provide evidence on the efficacy and safety of Ilomedin in patients with septic shock and persistent microcirculatory disorders. In systemic mean arterial pressure decreases below 65 mmHg after . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.